FSCN1 overexpression is documented in the majority of cancers, including ovarian [37], breast [38], colon [39], pancreatic [40,41], glioma [42], melanoma [43], leukemia [44], lymphoma [45], and esophageal squamous cell carcinoma [46]; however, the underlying molecular mechanisms of FSCN1 activation during the onset and progression of cancer are still understated. Here, FSCN1 is linked to lymphoma.